| Patient | Ernest Hemingway |
|---|---|
| Date of birth | 1970-07-21 |
| Identifiers | MRN HR-ET003-SYN; SSN (made up) 000-03-7419 |
| Document date | 2026-08-31 |
| Author | Walter Brandt-Ochoa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: iron, liver, mood, memory and blood pressure. [S]
Mr. Hemingway returns six months after intake. He has had twenty-two phlebotomies, and the twenty-third is planned after today's blood tests. He has had no alcohol for about fifteen weeks and still takes naltrexone. His mood is steady; the monthly PHQ-9 with the behavioral health clinician was 6 at his preventive visit and is 5 today. He writes every morning and says names and words come to him more easily. Headaches are about once a week. On amlodipine 10 mg his home average is 124/76, with slight ankle swelling in the evenings. The echocardiogram was done this morning. His guns remain at the club; he would like to bring them home before the autumn shooting season, and this was discussed. [S]
| Element | Detail |
|---|---|
| Phlebotomy | Twenty-two sessions; the twenty-third today |
| Alcohol | None for about fifteen weeks; AUDIT-C 0 |
| Mood | PHQ-9 5; item 9 scored 0 |
| Home blood pressure | Average 124/76 on amlodipine 10 mg |
| Cognition | MoCA 27, from 25 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; weight down 5 kg since intake |
| Cardiovascular | Positive | Slight ankle swelling in the evenings; no chest pain or breathlessness |
| Neurological | Positive | Headaches about once a week; memory better |
| Psychiatric | Negative | Mood steady; no thoughts of suicide or wishes to be dead since the last visit |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking | One tablet daily | Oral route | 2026-03-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-08-31 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-06-08 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 | active | S |
| Cephalexin 500 mg oral capsule, one capsule four times daily for seven days | One capsule four times daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Doxycycline hyclate 100 mg oral capsule, one capsule twice daily for seven days, with a full glass of water, sitting upright | One capsule twice daily for seven days | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for pain, no more than 2,000 mg a day while he is drinking | One or two tablets every 6 hours as needed, up to 2,000 mg a day | Oral route | 2026-05-11 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-31 | Body height | 183 | cm | S |
| 2026-08-31 | Body weight | 92.8 | kg | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 27.7 | kg/m2 | S |
| 2026-08-31 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-31 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-31 | Heart rate | 72 | /min | S |
| 2026-08-31 | Respiratory rate | 14 | /min | S |
| 2026-08-31 | Body temperature | 36.6 | Cel | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-31 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.5-17.5 g/dL | Low | S |
| 2026-08-31 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 93 | fL | 80-100 fL | Normal | S |
| 2026-08-31 | Platelets [#/volume] in Blood by Automated count | 226 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-31 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 2026-08-31 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-08-31 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 8-61 U/L | Normal | S |
| 2026-08-31 | Iron [Mass/volume] in Serum or Plasma | 148 | ug/dL | 65-175 ug/dL | Normal | S |
| 2026-08-31 | Iron saturation [Mass Fraction] in Serum or Plasma | 44 | % | 20-50% | Normal | S |
| 2026-08-31 | Ferritin [Mass/volume] in Serum or Plasma | 268 | ng/mL | 24-336 ng/mL | Normal | S |
| 2026-08-31 | Cholesterol [Mass/volume] in Serum or Plasma | 194 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-31 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 114 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-31 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 49 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-31 | Triglyceride [Mass/volume] in Serum or Plasma | 136 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-31 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | 4-5.6% | High | S |
| 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-31 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-08-31 | Total score [MoCA] | 27 | {score} | S |
Vital signs recorded on 2026-08-31; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 72; weight 92.8 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |
| Abdomen | Liver not palpable; no spleen felt |
| Neurological | No tremor; gait normal |
| Psychiatric | Bright, humorous and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis. |
| Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload) | resolved | confirmed | R79.0 | S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis. |
| Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imaging | active | confirmed | E83.110 | S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it. |
| Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used. |
| Essential hypertension, stage 2, with heavy drinking contributing | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home readings. |
| Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosed | active | confirmed | F07.81 | S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms. |
| Prediabetes (HbA1c 6.1%) | active | confirmed | R73.03 | S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes. |
| Fishhook puncture wound of the right hand with early cellulitis after saltwater exposure, in a man with iron overload; treated with antibiotics covering Vibrio; resolved | resolved | confirmed | L03.113 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin before each phlebotomy (hold if under 12.0 g/dL) | Before every session; full blood count at visits | Completed today | Hemoglobin 13.4 g/dL, MCV 93 fL, platelets 226 |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 268 ng/mL after twenty-two sessions |
| Laboratory | Transferrin saturation | At diagnosis and as ferritin nears target | Completed today | Serum iron 148 ug/dL; transferrin saturation 44% |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Completed today | Twenty-two sessions; the twenty-third today |
| Imaging | Liver cancer surveillance | Every six months only with cirrhosis or advanced fibrosis | Not indicated | No advanced fibrosis |
| Imaging | Echocardiogram for iron-related heart disease | When symptoms or ECG changes, or with other cardiac indications | Completed today | Done today with the hypertension echocardiogram: no iron-related cardiomyopathy |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | No supplements; no raw shellfish |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 27, ALT 31 and GGT 41 U/L; normal |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | AUDIT-C 0; no alcohol for about fifteen weeks |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids |
| Medication safety | Thiamine | While drinking or malnourished | Completed today | Stopped today |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; monthly since the corrective action |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 100 mg; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms remain off-site by his choice, with safe storage planned for their return |
| Self-management | Psychotherapy (CBT) | Weekly, then every two weeks | Completed today | Reduced to every two weeks |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 126/78 in clinic; home average 124/76; weight 92.8 kg; trace ankle edema |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Completed today | Done this morning after the corrective action: mild concentric left ventricular hypertrophy, ejection fraction 60% |
| Laboratory | Lipid panel | Yearly | Completed today | Total cholesterol 194, LDL 114, HDL 49 and triglycerides 136 mg/dL |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 14 mg/g at intake |
| Laboratory | HbA1c | At diagnosis of prediabetes, then every six to twelve months | Completed today | HbA1c 5.9% |
| Survey | Cognitive screen (MoCA) | Baseline, then after three months with less or no alcohol | Completed today | MoCA 27 of 30, from 25; delayed recall improved |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches about once a week |
| Imaging | Brain imaging | Only for warning signs or decline | Not indicated | No warning signs; cognition improving |
Goal progress:
Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (2021); Prediabetes and Type 2 Diabetes: Screening (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Weekly phlebotomy until ferritin is 50 to 100 ng/mL, then maintenance. Review in three months. Psychotherapy every two weeks and monthly PHQ-9. Colonoscopy as scheduled. [S]